Complex Coacervated Microcapsules In Cream For Topical Delivery Of The Curcuminoids And Quercetin by Ang , Lee Fung
COMPLEX COACERVATED MICROCAPSULES 
IN CREAM FOR TOPICAL DELIVERY OF THE 
CURCUMINOIDS AND QUERCETIN 
 
 
 
 
 
 
 
 
ANG LEE FUNG 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2015 
 
COMPLEX COACERVATED MICROCAPSULES IN CREAM 
FOR TOPICAL DELIVERY OF THE CURCUMINOIDS AND QUERCETIN 
 
 
 
by 
 
 
 
ANG LEE FUNG 
 
 
 
 
Thesis submitted in fulfillment of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
December 2015 
 
ii 
 
ACKNOWLEDGEMENTS 
 
Studying for this PhD degree was made possible by commitment from 
individuals, organizations and institutions. It is vital that I acknowledge their 
assistance, contribution and commitment. 
This thesis owes its existence to the help, support, and inspiration of many 
people. In the first place, I would like to express my sincere appreciation and 
gratitude to my supervisor, Associate Prof. Dr. Yusrida Darwis for her unlimited 
support and encouragement during the past five years of my research. She has 
provided an optimum working environment at the Department of Pharmaceutical 
Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia. Her 
perpetual energy and enthusiasm in research had motivated all her advisees, 
including me. In addition, she was always accessible and willing to help her students 
with their research. As a result, research life became smooth and rewarding for me. 
Her uncompromising quest for excellence significantly shapes everyone at the 
department.  
I wish to express my sincere appreciation and gratitude to my co-supervisor, 
Associate Prof. Dr. Yvonne Tan Tze Fung for her guidance, help and patience.  
I am also indebted to Dr Koh Rhun Yian, who has not only been a source of 
enthusiasm and encouragement, but has also agreed, with her exceptional insights 
into cell culture, to serve and enrich my knowledge in the in vitro part of my 
research.  
iii 
 
All my lab buddies at the Pharmaceutical Technology Department made it a 
convivial place to work. In particular, I would like to thank Ms. Nor Atiqah, Mr. 
Arshad, Ms. Nor Azah, Mr. Jahanzeb, Ms. Reem, Mr. Ibrahim Ms. Madeeha and Ms. 
Thiruchelvi. 
Collective and individual acknowledgments are also owed to all the technical 
and non-technical staff of the School of Pharmaceutical Sciences, Universiti Sains 
Malaysia. Many thanks go in particular to Mr. Samsuddin, Mr. Roseli Hassan, Mr. 
Basri Jaafar, Mr. Ibrahim, Ms. Salida, Mr. Amiruddin and Mr. Azrollyzam. 
I have greatly appreciated the generous financial support from The Ministry of 
Science and Technology Malaysia (MOSTI) who provided the National Science 
Fellowship (NSF) for my study. 
My deepest gratitude goes to my family for their unflagging love and support 
throughout my life; this dissertation is simply impossible without them. I want to 
thank my late father, Mr. Ang Ah Hua, for his care and love. I cannot ask for more 
from my mother, Mrs. Teng Boay Kee, as she is simply perfect. I have no suitable 
word that can fully describe her everlasting love to me. I am also grateful to my 
partner, Dr. M. F. Yam who was always my support in the moments when where was 
no one to answer my queries. 
Ang Lee Fung  
 
 
 
iv 
 
TABLES OF CONTENTS 
Acknowledgement ii 
Table of Contents iv 
List of Tables xiii 
List of Figures xvii 
List of Plates xxiv 
List of Abbreviations xxvii 
List of Appendices xxix 
Abstrak xxx 
Abstract xxxii 
 
CHAPTER 1 - INTRODUCTION 
1.1 Active ingredients 1 
 1.1.1 Curcuminoids/curcumin 1 
 1.1.2 Quercetin 4 
1.2 Microencapsulation 6 
 1.2.1 Introduction of microencapsulation 6 
 1.2.2 Core material 9 
 1.2.3 Coating material 9 
  1.2.3 (a) Gelatin 10 
  1.2.3 (b) Chitosan 14 
 1.2.4 Crosslinking agent 16 
  1.2.4 (a) Formaldehyde crosslinking mechanism 17 
 1.2.5 Classification of microcapsules and microspheres 19 
 1.2.6 Coacervation microencapsulation 20 
  1.2.6 (a) Complex coacervation systems 20 
  1.2.6 (b) Complex coacervation microencapsulation 
process 
21 
 1.2.7 Release mechanism of microcapsules 25 
 1.2.8 Advantages of microencapsulation 27 
 1.2.9 Application of microcapsules to end product 28 
 1.2.10 Microcapsule controlled drug delivery system 29 
v 
 
1.3 Topical drug delivery 29 
 1.3.1 Cream and emulsion 30 
  1.3.1 (a) Surfactant and the HLB system 31 
  1.3.1 (b) Characterization of cream 34 
  1.3.1 (c) Stability of cream 37 
1.4 Wound healing 40 
 1.4.1 Wound and wound types 40 
 1.4.2 Degree of wound 41 
 1.4.3 Degree of burn wound 42 
 1.4.4 Mechanisms of wound healing 42 
1.5 Statement of the problem 44 
1.6 Objectives 44 
    
CHAPTER 2 - HPLC METHOD DEVELOPMENT AND VALIDATION FOR 
SIMULTANEOUS DETERMINATION OF QUERCETIN 
AND CURCUMINOIDS 
2.1 Introduction 46 
2.2 Materials and methods 49 
 2.2.1 Materials 49 
 2.2.2 Methods 50 
 2.2.2.1 HPLC instrumentation 50 
 2.2.2.2 Chromatographic conditions 50 
 2.2.2.3 Preparation of standard and quality control solutions 50 
 2.2.2.4 Limit of detection, limit of quantitation and limit of 
linearity 
51 
 2.2.2.5 Construction of calibration curves 51 
 2.2.2.6 Validation 52 
  2.2.2.6 (a) Specificity 52 
  2.2.2.6 (b) Precision and accuracy 52 
  2.2.2.6 (c) Robustness 53 
 2.2.2.7 System suitability testing 53 
2.3 Results 54 
 2.3.1 Limit of detection, limit of quantitation and limit of 
linearity 
54 
vi 
 
 2.3.2 Calibration curve 55 
 2.3.3 Specificity 59 
 2.3.4 Precision and accuracy 60 
 2.3.5 Robustness 61 
 2.3.6 System suitability testing 68 
2.4 Discussion 69 
2.5 Conclusion 71 
    
CHAPTER 3 - PREPARATION AND OPTIMIZATION OF PROCESS 
VARIABLES OF TYPE B GELATIN /CHITOSAN COMPLEX 
COACERVATION 
3.1 Introduction 72 
3.2 Materials and methods 73 
 3.2.1 Materials 73 
 3.2.2 Methods 74 
 3.2.2.1 Electrophoretic studies 74 
 3.2.2.2 Standard procedure for gelatin-chitosan complex 
coacervation 
74 
 3.2.2.3 Observation of coacervate morphology 74 
 3.2.2.4 Degree of coacervation 75 
 3.2.2.5 Optimization of complex coacervation variables 75 
  3.2.2.5 (a) pH of coacervation 75 
  3.2.2.5 (b) Total polymer concentration and polymer 
mixing ratio 
76 
  3.2.2.5 (c) Coacervation temperature 76 
  3.2.2.5 (d) Coacervation duration 77 
  3.2.2.5 (e) Incubation time 77 
 3.2.2.6 Coacervate droplet size 77 
3.3 Results 78 
 3.3.1 Electrophoretic studies 78 
 3.3.2 pH of coacervation 79 
 3.3.3 Total polymer concentration and polymer mixing ratio 83 
 3.3.4 Coacervation temperature 91 
 3.3.5 Coacervation duration 92 
vii 
 
 3.3.6 Incubation time 94 
3.4 Discussion 96 
3.5 Conclusion 102 
   
CHAPTER 4 - PREPARATION AND CHARACTERIZATION OF 
THE CURCUMINOIDS AND QUERCETIN 
MICROCAPSULES BY GELATIN B-CHITOSAN 
COMPLEX COACERVATION 
 
4.1 Introduction  104 
4.2 Materials and methods 106 
 4.2.1 Materials 106 
 4.2.2 Methods 106 
 4.2.2.1 Solubility of curcuminoids and quercetin in various 
mediums 
106 
 4.2.2.2 Quantitation of curcuminoids and quercetin content in 
microcapsules 
107 
 4.2.2.3 Complex coacervation microencapsulation and 
optimization – Investigation of curcuminoids and quercetin 
solid core microencapsulation 
108 
 4.2.2.4 Curcuminoids/quercetin liquid core microencapsulation 110 
 4.2.2.5 Determination of microencapsulation efficiency 111 
 4.2.2.6 Physical characterization of microcapsules 112 
  4.2.2.6 (a) Microcapsule particle size 112 
  4.2.2.6 (b) Microcapsule wall thickness 112 
  4.2.2.6 (c) Morphology observation by optical microscope 112 
  4.2.2.6 (d) Morphology observation by SEM 112 
  4.2.2.6 (e) Colorimetric evaluation 113 
  4.2.2.6 (f) Appearance and staining testing 113 
  4.2.2.6 (g) Hygroscopicity 113 
 4.2.2.7 Physicochemical characterization 114 
  4.2.2.7 (a) Differential scanning calorimetry (DSC) 114 
  4.2.2.7 (b) Fourier transform infrared spectroscopy 114 
 4.2.2.8 Light stability 115 
 4.2.2.9 Storage stability 115 
 4.2.2.10 Swelling studies 116 
 4.2.2.11 Permeation study by using Franz diffusion cell 117 
viii 
 
 4.2.2.12 Drug release kinetics study 119 
 4.2.2.13 Determination of residual formaldehyde by gas 
chromatography 
120 
  4.2.2.13 (a) Chemicals and reagents 120 
  4.2.2.13 (b) Instruments 121 
 4.2.2.14 Statistical analysis 121 
4.3 Results 122 
 4.3.1 Solubility of curcuminoids and quercetin in various 
mediums 
122 
 4.3.2 Quantitation of curcuminoids and quercetin content in 
microcapsules 
122 
 4.3.3 Complex coacervation microencapsulation and 
optimization –Investigation of curcuminoids and quercetin 
solid core microcapsules 
125 
  4.3.3 (a) Influence of pH changing rate on microcapsule 
particle size and size distribution 
125 
  4.3.3 (b) Effect of drug concentration 127 
  4.3.3 (c) Effect of microencapsulation equilibrium time 128 
  4.3.3 (d) Effect of Tween 80 concentration 129 
  4.3.3 (e) Effect of formaldehyde crosslinking 130 
  4.3.3 (f) Effect of agitation rate 131 
  4.3.3 (g) Effect of manner of agitation  134 
 4.3.4 Curcuminoids/quercetin liquid core microencapsulation 136 
 4.3.5 Physical characterization of microcapsules 136 
  4.3.5 (a) Morphology, wall thickness and particle size 136 
  4.3.5 (b) Morphology observation by SEM 141 
  4.3.5 (c) Colorimetric evaluation 143 
  4.3.5 (d) Appearance and staining testing 144 
  4.3.5 (e) Hygroscopicity 147 
 4.3.6 Physicochemical characterization of microcapsules 147 
  4.3.6 (a) Differential scanning calorimetry (DSC) 147 
  4.3.6 (b) Fourier transform infrared spectroscopy 152 
 4.3.7 Light stability 161 
 4.3.8 Storage stability 163 
 4.3.9 Swelling studies 168 
 4.3.10 Permeation studies by Franz diffusion cell 169 
ix 
 
 4.3.11 Drug release kinetics study 170 
 4.3.12 Determination of residual formaldehyde by gas 
chromatography 
173 
4.4 Discussion  174 
4.5 Conclusion  185 
   
CHAPTER 5 - FORMULATION AND CHARACTERIZATION OF 
MICROCAPSULE INCORPORATED CREAMS FOR 
TOPICAL APPLICATION 
5.1 Introduction  186 
5.2 Materials and methods 190 
 5.2.1 Materials 190 
 5.2.2 Methods 191 
 5.2.2.1 Construction of ternary phase diagram 191 
  5.2.2.1 (a) Fabrication of area of interest 191 
  5.2.2.1 (b) Fabrication of pseudo-ternary phase diagram 
and domain 
192 
 5.2.2.2 Mixture design 192 
 5.2.2.3 Preparation of O/W creams and optimization of mixing 
methods 
194 
 5.2.2.4 Cream characterization 195 
  5.2.2.4 (a) Organoleptic properties 195 
  5.2.2.4 (b) Cream type examination 195 
  5.2.2.4 (c) Microscopy observation 195 
  5.2.2.4 (d) Cream pH 196 
  5.2.2.4 (e) Zeta potential 196 
  5.2.2.4 (f) Particle size 196 
  5.2.2.4 (g) Rheological properties 197 
  5.2.2.4 (h) Texture analysis 198 
 5.2.2.5 Drug content 199 
 5.2.2.6 In vitro drug diffusion studies 199 
 5.2.2.7 Drug release kinetics studies 200 
 5.2.2.8 Stress testing 201 
  5.2.2.8 (a) Centrifugation test 201 
  5.2.2.8 (b) Freeze-thaw cycles test 201 
x 
 
 5.2.2.9 Storage stability 201 
 5.2.2.10 Skin irritation test 202 
 5.2.2.11 Statistical analysis 203 
5.3 Results  204 
 5.3.1 Construction of ternary phase diagram 204 
  5.3.1 (a) Fabrication of area of interest 204 
  5.3.1 (b) Fabrication of pseudo-ternary phase diagram and 
domain 
205 
 5.3.2 Mixture design 207 
  5.3.2 (a) Mixture experimental design 207 
  5.3.2 (b) Model establishment 211 
  5.3.2 (c) Determination of the influence of design variables 214 
  5.3.2 (d) Formulation optimization 218 
 5.3.3 Preparation of O/W creams and optimization of mixing 
methods 
219 
 5.3.4 Cream characterization 223 
  5.3.4 (a) Organoleptic properties 223 
  5.3.4 (b) Cream type examination 224 
  5.3.4 (c) Microscopy observation 224 
  5.3.4 (d) Cream pH 225 
  5.3.4 (e) Zeta potential 226 
  5.3.4 (f) Particle size 227 
  5.3.4 (g) Rheological properties 227 
  5.3.4 (h) Texture analysis 229 
 5.3.5 Drug content 230 
 5.3.6 In vitro drug diffusion studies 232 
 5.3.7 Drug release kinetics studies 233 
 5.3.8 Stress testing 235 
  5.3.8 (a) Centrifugation test 235 
  5.3.8 (b) Freeze–thaw cycles test 235 
 5.3.9 Storage stability 235 
  5.3.9 (a) Organoleptic properties 235 
  5.3.9 (b) Cream pH 235 
xi 
 
  5.3.9 (c) Zeta potential 237 
  5.3.9 (d) Particle size 238 
  5.3.9 (e) Rheological properties 241 
  5.3.9 (f) Texture analysis 242 
  5.3.9 (g) Drug content 243 
 5.3.10 Skin irritation test 248 
5.4 Discussion 255 
5.5 Conclusion  265 
    
CHAPTER 6 - ANTIOXIDANT, ANTIBACTERIAL AND WOUND 
HEALING PROPERTIES OF CURCUMINOIDS AND 
QUERCETIN IN NATIVE AND MICROCAPSULE 
FORMS 
 
6.1 Introduction  266 
6.2 Materials and methods 268 
 6.2.1 Materials 268 
 6.2.2 Methods 269 
 6.2.2.1 Antioxidant activity 269 
  6.2.2.1 (a) Trolox equivalent antioxidant capacity (TEAC) 269 
  6.2.2.1 (b) Assessment of DPPH scavenging activity 270 
 6.2.2.2 Minimum inhibitory concentration 271 
 6.2.2.3 Effect of curcuminoids/quercetin and its encapsulated form 
on HaCaT cell 
272 
  6.2.2.3 (a) Cell culture and treatments 272 
  6.2.2.3 (b) Cell cytotoxicity/viability determination by 3-
(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide (MTT) assay 
273 
  6.2.2.3 (c) Cell proliferation determination by 3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium 
bromide (MTT) assay 
273 
  6.2.2.3 (d) Cell migration determination by wound scratch 
assay 
274 
 6.2.2.4 Effect of curcuminoids and quercetin microcapsule 
incorporated creams as controlled drug delivery on wound 
healing 
274 
  6.2.2.4 (a) Animal models 275 
  6.2.2.4 (b) Burn wound 275 
  6.2.2.4 (c) Treatment 276 
xii 
 
  6.2.2.4 (d) Measurement of hydroxyproline 277 
  6.2.2.4 (e) Histopathologic study 277 
  6.2.2.5 Statistical analysis 278 
6.3 Results 278 
 6.3.1 Antioxidant activity 278 
  6.3.1 (a) Trolox equivalent antioxidant capacity (TEAC) 278 
  6.3.1 (b) Assessment of DPPH scavenging activity 279 
 6.3.2 Minimum inhibitory concentration 280 
 6.3.3 Effect of curcuminoids/quercetin and its encapsulated form 
on HaCaT cell 
281 
  6.3.3 (a) Cell cytotoxicity/viability determination by 3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium 
bromide (MTT) assay 
281 
  6.3.3 (b) Cell proliferation determination by 3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium 
bromide (MTT) assay 
283 
  6.3.3 (c) Cell migration determination by wound scratch 
assay 
284 
 6.3.4 Effect of curcuminoids and quercetin microcapsule 
incorporated creams as controlled drug delivery on wound 
healing 
285 
  6.3.4 (a) Wound contraction 285 
  6.3.4 (b) Measurement of hydroxyproline 292 
  6.3.4 (c) Histopathologic study 293 
6.4 Discussion  295 
6.5 Conclusion  302 
  
CHAPTER 7 - SUMMARY AND CONCLUSION 304 
CHAPTER 8 - SUGGESTIONS FOR FUTURE RESEARCH 307 
REFERENCES 309 
APPENDICES  
LIST OF PUBLICATIONS  
 
 
 
xiii 
 
LIST OF TABLES 
  Page 
Table 1.1 A summary of surfactant HLB ranges and their applications 
 
32 
Table 1.2 Required hydrophilic-lipophilic balance (rHLB) for some 
oil-phase ingredients for oil-in-water (O/W) and water-in-oil 
(W/O) emulsions 
 
34 
Table 2.1 LOD, LOQ, LOL and linear regression analysis parameters 
for quercetin (QUE) and curcuminoids (BDMC, DMC and 
CUR) 
 
54 
Table 2.2 Retention times and responses data for calibration standards 
of quercetin (QUE) and curcuminoids (BDMC, DMC and 
CUR) 
 
56 
Table 2.3 Precision and accuracy for intraday and interday repetitions 
for the quantitative detection of quercetin (QUE) and 
curcuminoids (BDMC, DMC and CUR) 
 
61 
Table 2.4a Robustness parameters: (a) Change in the organic 
composition by ± 2.0% 
 
63 
Table 2.4b Robustness parameters: (b) Change in the acetic acid 
concentration by ± 1.0% v/v 
 
64 
Table 2.4c Robustness parameters: (c) Change in the flow rate of ± 0.1 
ml/min 
 
65 
Table 2.4d Robustness parameters: (d) Change in the column 
temperature of ± 5.0 °C 
 
66 
Table 2.5 System suitability parameters, calculation formula and 
recommendations 
 
68 
Table 2.6 System suitability testing 
 
69 
Table 3.1 Coarcervate droplet size and size distribution at different 
total polymer concentrations and different mixing ratios for 
gelatin-chitosan systems  
 
85 
Table 3.2 Effect of reaction temperature on coarcervate droplet size 
and size distribution of gelatin-chitosan systems at total 
polymer concentration of 2.55% w/w and mixing ratio of 
30:1 
 
92 
Table 3.3 Effect of coacervation duration on coarcervate droplet size 
and size distribution of the gelatin-chitosan systems at total 
polymer concentration of 2.55% w/w and mixing ratio of 
94 
xiv 
 
30:1 
 
Table 3.4 Effect of incubation time on coarcervate droplet size and size 
distribution of gelatin-chitosan systems at total polymer 
concentration of 2.55% w/w and mixing ratio of 30:1 
 
95 
Table 4.1 Solubility of curcumin and quercetin in various mediums 
 
122 
Table 4.2 Effect of disruption method on solubility of curcumin from 
curcuminoids microcapsule 
 
123 
Table 4.3 Particle size and size distribution influenced by pH 
adjustment rate using sodium hydroxide  
 
125 
Table 4.4 Effect of drug loaded amount on microencapsulation 
efficiency 
 
128 
Table 4.5 Effect of microencapsulation equilibrium time on 
microencapsulation efficiency 
 
129 
Table 4.6 Effect of Tween 80 concentration on microencapsulation 
efficiency 
 
130 
Table 4.7 Effect of formaldehyde concentration on microencapsulation 
efficiency 
 
131 
Table 4.8 Effect of formaldehyde crosslinking reaction time on 
microencapsulation efficiency 
 
131 
Table 4.9 Effect of agitation rate on microencapsulation efficiency 
 
132 
Table 4.10 Effect of agitation rate during microencapsulation on particle 
size and size distribution 
 
133 
Table 4.11 Effect of manner of agitation on microencapsulation 
efficiency for crosslinked- and uncrosslinked microcapsules 
 
134 
Table 4.12 The summary of optimized parameters for curcuminoids and 
quercetin solid core microencapsulation prepared by gelatin-
chitosan complex coacervation (total polymer concentration 
was 2.55% w/w using gelatin:chitosan ratio of 30:1) 
 
135 
Table 4.13 Entrapment efficiency, drug loading and yield for CPM, 
QPM, CLM and QLM at optimized conditions 
 
136 
Table 4.14 Particle size and wall thickness for CPM, QPM, CLM and 
QLM 
 
138 
Table 4.15 Color space values for native drugs and microcapsules  143 
xv 
 
Table 4.16 Hygroscopicity of microcapsules and native drug powders of 
curcuminoids and quercetin, samples stored at room 
temperature (28 ± 4 °C/75 ± 10% RH) for one week 
 
147 
Table 4.17 Rate equation reactant concentration-time profiles and half-
lives for zero-, first-, and second order reactions 
 
161 
Table 4.18 Values of coefficient of determination (R2), rate constant (k) 
and half-life of degradation (t1/2) for curcuminoids, 
quercetin, CPM, CLM, QPM and QLM 
 
162 
Table 4.19 Exponent of the Korsmeyer-Peppas model and drug release 
mechanism for spherical geometry matrices 
 
172 
Table 4.20 Parameters of drug release kinetic models for native drug 
powders of curcuminoids and quercetin, and microcapsules 
of CPM and QPM 
 
172 
Table 5.1 Limits of the experimental domain 
 
208 
Table 5.2 Mixture design experiments and responses analyses for 2% 
curcuminoids microcapsule (CPM) incorporated creams with 
total required HLB of 10.325 
 
209 
Table 5.3 Mixture design experiments and responses analyses for 2% 
curcuminoids microcapsule (CPM) incorporated creams with 
total required HLB of 10.875 
 
210 
Table 5.4 Predicted response values with confidence interval (CI), 
prediction interval (PI) and standard errors (SE) analyzed by 
Design Expert® software DX6 for optimized cream 
formulation of oil phase:emulsifiers blend:aqueous phase = 
30:12.95:57.05 (% w/w) 
 
219 
Table 5.5 Formulation of oil-in-water cream incorporated with 2% 
w/w curcuminoids (CPM)/quercetin (QPM) microcapsules 
 
219 
Table 5.6 Effect of mixing methods during emulsification on emulsion 
particle size and size distribution 
 
220 
Table 5.7 pH, particle size and zeta potential measurements of freshly 
prepared curcuminoids (CPM) and quercetin (QPM) creams 
 
225 
Table 5.8 Rheological properties of curcuminoids microcapsule (CPM) 
cream, quercetin microcapsule (QPM) cream and some 
marketed topical creams 
 
228 
Table 5.9 Firmness and work of shear values for curcuminoids 
microcapsule (CPM) cream, quercetin microcapsule (QPM) 
cream and some marketed topical creams  
230 
xvi 
 
Table 5.10 Parameters of drug release kinetic models for curcuminoids 
microcapsule (CPM), quercetin microcapsule (QPM), CPM 
incorporated cream and QPM incorporated cream 
 
234 
Table 5.11 Ritger-Peppas diffusion exponent and mechanism of 
diffusional release from various swellable controlled release 
system 
 
234 
Table 5.12 Apparent viscosity and thixotropy of curcuminoids 
microcapsule (CPM) creams stored at 28 ± 4 °C/75 ± 10% 
RH and 40 ± 2 °C/75 ± 5% RH for 6 months; mean ± SD, n 
= 3 
 
241 
Table 5.13 Apparent viscosity and thixotropy of quercetin microcapsule 
(QPM) creams stored at 28 ± 4 °C/75 ± 10% RH and 40 ± 2 
°C/75 ± 5% RH for 6 months; mean ± SD, n = 3 
 
242 
Table 5.14 Work of shear and firmness of curcuminoids microcapsule 
(CPM) creams stored at 28 ± 4 °C/75 ± 10% RH and 40 ± 2 
°C/75 ± 5% RH for 6 months; mean ± SD, n = 3 
 
242 
Table 5.15 Work of shear and firmness of quercetin microcapsule 
(QPM) creams stored at 28 ± 4 °C/75 ± 10% RH and 40 ± 2 
°C/75 ± 5% RH for 6 months; mean ± SD, n = 3 
 
243 
Table 5.16 Drug remaining (mg) and percent drug remaining (in 
bracket) of 2% w/w microcapsule (CPM/QPM) incorporated 
creams stored at 28 ± 4 °C/75 ± 10% RH and 40 ± 2 °C/75 ± 
5% RH for 6 months 
 
245 
Table 5.17 Parameters of simple kinetic models for CPM cream and 
QPM cream stored at room temperature (28 ± 4 °C/75 ± 10% 
RH) and elevated temperature (40 ± 2 °C/75 ± 5% RH) for 6 
months  
 
245 
Table 5.18 Grading of skin reactions 
 
248 
Table 6.1 Antioxidant activity of curcuminoids and quercetin (both in 
native and microcapsule forms), BHA and BHT  
 
279 
Table 6.2 Minimum inhibitory concentrations of curcuminoids and 
quercetin (both in native and microcapsule forms) and 
antibiotics of gram positive and gram negative bacteria 
 
 
 
 
 
280 
 
xvii 
 
LIST OF FIGURES 
  Page 
Figure 1.1 Chemical structures of curcumin, demethoxycurcumin and 
bisdemethoxycurcumin 
 
3 
Figure 1.2 Chemical structure of quercetin 
 
5 
Figure 1.3 Schematic morphologies of different types of 
microcapsules: (A) matrix,  (B) single structure 
microcapsule (regular), (C) irregular single structure 
microcapsule, (D) multiwall microcapsule, (E) multi-core 
microcapsule and (F) aggregate structure microcapsule 
 
8 
Figure 1.4 Chemical structure of gelatin 
 
13 
Figure 1.5 Chemical structure of chitosan 
 
14 
Figure 1.6 Formation of methylene glycol and formaldehyde polymer 
 
17 
Figure 1.7 Formaldehyde crosslinking: formation of methylene glycol 
and methylene bridge 
 
18 
Figure 1.8 Schematic morphologies of (a) microcapsule and (b) 
microsphere 
 
19 
Figure 1.9 Process of microencapsulation by complex coacervation: (a) 
emulsification or suspension of core ingredients in the 
vehicle phase (typically aqueous solution); (b) induce 
complex coacervation by addition of a second complexing 
hydrocolloid; (c) solidification of wall materials and 
crosslink to stabilize the microcapsules; and (d) washing 
and drying 
 
23 
Figure 1.10 Schematic representation of microencapsulation by 
coacervation: (a) dispersed liquid or solid drug particles, (b) 
induction of phase separation, (c) deposition of 
microdroplets at the surface, and (d) fusion into a membrane 
 
24 
Figure 1.11 Drug release mechanisms from microcapsules: (a) diffusion, 
(b) dissolution, (c) osmosis, and (d) erosion 
 
27 
Figure 1.12 Common breadown processes of emulsions  
 
40 
Figure 2.1 Chemical structures of quercetin, bisdemethoxycurcumin, 
demethoxycurcumin and curcumin 
 
47 
Figure 2.2 Quercetin calibration curve 
 
57 
xviii 
 
Figure 2.3 Bisdemethoxycurcumin calibration curve 
 
57 
Figure 2.4 Demethoxycurcumin calibration curve 
 
58 
Figure 2.5 Curcumin calibration curve 
 
58 
Figure 2.6 Chromatogram of QUE, quercetin; BDMC, 
bisdemethoxycurcumin; DMC, demethoxycurcumin; and 
CUR, curcumin 
 
59 
Figure 2.7 Chromatograms of (a) methanol, (b) ethanol, (c) mobile 
phase, (d) citrate-phosphate buffer pH 5.4, (e) cream base 
and (f) gelatin-chitosan coacervate microcapsule 
 
60 
Figure 2.8 Combined chromatograms of quercetin (QUE), 
bisdemethoxycurcumin (BDMC), demethoxycurcumin 
(DMC) and curcumin (CUR) analyzed at different 
conditions: (a) change in the organic composition by ± 2%; 
(b) change in the acetic acid concentration by ± 1.0% v/v; 
(c) change in the flow rate of mobile phase of ± 0.1 ml/min; 
and (d) change in the column temperature of ± 5.0 °C 
 
67 
Figure 3.1 Zeta potential measurements as a function of pH: (a) 
chitosan solution (0.04% w/w), and (b) type B gelatin 
solution (1% w/w) with ionic strength of 0.1 M NaCl, 
performed at 25 °C. Mean ± SD, n = 3 
 
79 
Figure 3.2 Effect of pH on turbidity index and dry coacervate yield of 
gelatin-chitosan systems at total polymer concentration of 
2.55% w/w and mixing ratio of 30:1. The process was 
carried out by constant stirring at 500 rpm for 0.5 h, at 50 
°C. Mean ± SD, n = 3 
 
81 
Figure 3.3 Effect of total polymer concentration and gelatin-chitosan 
mixing ratio on turbidity index. Coacervations were induced 
at pH 5.50 with constant stirring for 0.5 h, at 50 °C. Mean ± 
SD, n = 3 
 
88 
Figure 3.4 Dry coacervate yields obtained from gelatin-chitosan 
systems at different total polymer concentrations and 
different mixing ratios. Coacervations were induced at pH 
5.50 with constant stirring at 500 rpm for 0.5 h, at 50 °C. 
Mean ± SD, n = 3 
 
90 
Figure 3.5 Different coacervate volumes and dry coacervate yields 
obtained from gelatin-chitosan systems at ratio of 30:1, of 
different total polymer concentrations. Coacervations were 
induced at pH 5.50 with constant stirring at 500 rpm for 0.5 
h, at 50 °C Mean ± SD, n = 3 
 
90 
xix 
 
Figure 3.6 Effect of coacervation temperature on turbidity index and 
dry coacervate yield of gelatin-chitosan systems at total 
polymer concentration of 2.55% w/w and mixing ratio of 
30:1. Coacervations were induced at pH 5.50 with constant 
stirring at 500 rpm for 0.5 h.  Mean ± SD, n = 3 
 
91 
Figure 3.7 Effect of coacervation duration of the gelatin-chitosan 
systems at total polymer concentration of 2.55% w/w and 
mixing ratio of 30:1 on colloids turbidity index and dry 
coacervate yield. The pH and temperature of coacervation 
were 5.50 and 50 °C, respectively. Mean ± SD, n = 3 
 
93 
Figure 3.8 Effect of incubation time of gelatin-chitosan systems at total 
polymer concentration of 2.55% w/w and mixing ratio of 
30:1 on turbidity index and dry coacervate yield. The 
coacervations were induced at pH 5.50 with constant 
stirring at 500 rpm for 0.5 h, at 50 °C. Mean ± SD, n = 3 
 
95 
Figure 4.1 Schematic diagram for the preparation of gelatin-chitosan 
coacervation microcapsules containing solid or liquid core 
materials 
 
111 
Figure 4.2 The static Franz cell and the experimental setup using #V3 
3-Station Franz Cell Stirrer 
 
118 
Figure 4.3 HPLC chromatograms of (a) CPM, curcuminoids solid core 
microcapsule; (b) CLM, curcuminoids liquid core 
microcapsule; (c) QPM, quercetin solid core microcapsule 
and (d) QLM, quercetin liquid core microcapsule 
 
124 
Figure 4.4 Effect of pH changing rate on particle size distribution for 
curcuminoids solid core microcapsules: (a) 25 µl/10 sec and 
(b) 200 µl/10 sec  
 
126 
Figure 4.5 DSC thermograms of raw material powders: gelatin, 
chitosan, curcuminoids and quercetin  
 
148 
Figure 4.6 DSC thermograms of crosslinked CPM, uncrosslinked 
CPM, crosslinked CLM, blank microcapsule and physical 
mixtures of raw materials 
 
151 
Figure 4.7 DSC thermograms of crosslinked QPM, uncrosslinked 
QPM, crosslinked QLM, blank microcapsule and physical 
mixtures of raw materials  
 
151 
Figure 4.8 FTIR spectra of gelatin, chitosan and blank microcapsule 
 
154 
Figure 4.9 FTIR spectra of native curcuminoids and quercetin powders 
 
155 
Figure 4.10 FTIR spectra of blank microcapsule, CPM and CLM 158 
xx 
 
Figure 4.11 FTIR spectra of blank microcapsule, QPM and QLM 
 
159 
Figure 4.12 FTIR overlay spectra of CPM and CLM 
 
160 
Figure 4.13 FTIR overlay spectra of QPM and QLM 
 
160 
Figure 4.14 Zero order kinetics plots of light stability data for native 
curcuminoids, CPM and CLM. Data points are mean value 
of triplicate measurements 
 
162 
Figure 4.15 First order kinetics plots of light stability data for native 
curcuminoids, CPM and CLM. Data points are mean value 
of triplicate measurements 
 
163 
Figure 4.16 Drug retention of native curcuminoids, native quercetin, 
CPM, QPM, CLM and QLM stored at 28 ± 4 °C/75 ± 10% 
RH for 12 months. ** and *** indicate significant 
difference at p < 0.01 and at p < 0.001, respectively 
compared to control. Mean ± SD, n = 3 
 
164 
Figure 4.17 Drug retention of native curcuminoids, native quercetin, 
CPM, QPM, CLM and QLM stored at 40 ± 2 °C/75 ± 5% 
RH for 6 months. *** indicates significant difference at p < 
0.001 compared to control. Mean ± SD, n = 3 
 
165 
Figure 4.18 Drug retention of native curcuminoids, native quercetin, 
CPM, QPM, CLM and QLM stored at 5 ± 3 °C for 6 
months. ** and *** indicate significant difference at p < 
0.01 and at p < 0.001, respectively compared to control. 
Mean ± SD, n = 3 
 
165 
Figure 4.19 Particle size of CPM, QPM, CLM and QLM stored at 28 ± 
4 °C/75 ± 10% RH for 12 months. *** indicates significant 
difference at p < 0.001 compared to control. Mean ± SD, n 
= 3 
 
166 
Figure 4.20 Particle size of CPM, QPM, CLM and QLM stored at 40 ± 
2 °C/75 ± 5% RH for 6 months. ** and *** indicate 
significant difference at p < 0.01 and at p < 0.001, 
respectively compared to control. Mean ± SD, n = 3 
 
167 
Figure 4.21 Particle size of CPM, QPM, CLM and QLM stored at 5 ± 3 
°C for 6 months. Mean ± SD, n = 3 
 
167 
Figure 4.22 Comparison of swelling index for various microcapsules in 
different media at 35 ± 2 °C. Mean ± SD, n = 3 
 
168 
Figure 4.23 Release profiles of native curcuminoids, crosslinked CPM 
and uncrosslinked CPM 
 
169 
xxi 
 
Figure 4.24 Release profiles of native quercetin, crosslinked QPM and 
uncrosslinked QPM  
 
170 
Figure 4.25 Chromatograms of formaldehyde analysis by gas 
chromatography: (a) internal standard solution (1-butanol), 
(b) standard solution containing 0.1% formaldehyde and 1-
butanol, (c) crosslinked CPM and (d) crosslinked QPM  
 
173 
Figure 5.1 The set-up of TTC Spreadability fixture on the Heavy Duty 
Platform  
 
199 
Figure 5.2 Pseudo-ternary phase diagram of oil, water and emulsifiers 
blend showing oil-in-water region  
 
205 
Figure 5.3 Combination points in area of interest of ternary phase 
diagram and the oil-in-water cream formulations 
(highlighted area) 
 
206 
Figure 5.4 Construction of pseudo ternary phase diagram (L-
transformation) and parallelogram (domain) 
 
207 
Figure 5.5 The normal probability plots for experimental responses: (a) 
apparent viscosity, (b) firmness and (c) work of shear 
 
212 
Figure 5.6 The predicted versus actual plots for experimental 
responses: (a) apparent viscosity, (b) firmness and (c) work 
of shear 
 
213 
Figure 5.7 Response trace plots of (a) apparent viscosity, (b) firmness 
and (c) work of shear. A: oil components = 29.97%, B: 
emulsifiers blend = 12.97%, C: aqueous phase = 56.91% 
 
215 
Figure 5.8 3D surface plots: (a) apparent viscosity, (b) firmness and (c) 
work of shear. X1: oil phase, X2: emulsifier blend and X3: 
aqueous phase  
 
217 
Figure 5.9 Size distribution graphs of cream bases emulsified by: (a) 
mechanical mixing at 2000 rpm for 15 min, (b) mechanical 
mixing and homogenization at 18000 rpm for 2 min and (c) 
mechanical mixing and homogenization at 18000 rpm for 2 
min, 3 cycles 
 
221 
Figure 5.10 Zeta potential charge distribution of curcuminoids 
microcapsule (CPM) cream (n = 3) 
 
226 
Figure 5.11 Zeta potential charge distribution of quercetin microcapsule 
(QPM) cream (n = 3) 
 
226 
Figure 5.12 Rheograms of (a) curcuminoids microcapsule (CPM) cream 
and (b) quercetin microcapsule (QPM) cream 
229 
xxii 
 
Figure 5.13 HPLC chromatograms of (a) curcuminoids microcapsule 
(CPM) cream and (b) quercetin microcapsule (QPM) cream 
 
231 
Figure 5.14 In vitro drug release profiles of crosslinked curcuminoids 
microcapsule (CPM), crosslinked quercetin microcapsule 
(QPM), CPM cream and QPM cream  
 
232 
Figure 5.15 pH values of CPM and QPM creams stored at 28 ± 4 °C/75 
± 10% RH and 40 ± 2 °C/75 ± 5% RH for 6 months; mean 
± SD, n = 3. * represents significant difference compared to 
control at p < 0.05 
 
236 
Figure 5.16 Zeta potential values of CPM cream stored at 28 ± 4 °C/75 
± 10% RH and 40 ± 2 °C/75 ± 5% RH for 6 months; mean 
± SD, n = 3 
 
237 
Figure 5.17 Zeta potential values of QPM cream stored at 28 ± 4 °C/75 
± 10% RH and 40 ± 2 °C/75 ± 5% RH for 6 months; mean 
± SD, n = 3. * represents significant difference compared to 
control at p < 0.05 
 
238 
Figure 5.18 Particle size and span values of  CPM cream stored at 28 ± 
4 °C/75 ± 10% RH and 40 ± 2 °C/75 ± 5% RH for 6 
months; mean ± SD, n = 3. * represents significant 
difference compared to control at p < 0.05 
 
239 
Figure 5.19 Particle size and span values of QPM cream stored at 28 ± 4 
°C/75 ± 10% RH and 40 ± 2 °C/75 ± 5% RH for 6 months; 
mean ± SD, n = 3. * represents significant difference 
compared to control at p < 0.05 
 
239 
Figure 5.20 Size distribution of creams containing 2% w/w 
curcuminoids microcapsule (a-c) and 2% w/w quercetin 
microcapsule (d-f). Graphs (a) and (d) represented freshly 
prepared creams; graphs (b) and (e), (c) and (f) represented  
creams stored at 28 ± 4 °C/75 ± 10% RH and 40 ± 2 °C/75 
± 5% RH, respectively for 6 months 
 
240 
Figure 5.21 Simple order kinetic plots of drug degradation data for 
curcuminoids microcapsule (CPM) creams  
 
246 
Figure 5.22 Simple order kinetic plots of drug degradation data for 
quercetin microcapsule (QPM) creams  
 
247 
Figure 6.1 A modified stainless steel stamp (20 mm in diameter) with 
an electronic temperature controller 
 
276 
Figure 6.2 Effect of native curcuminoids, native quercetin, 
curcuminoids microcapsule (CPM) and quercetin 
microcapsule (QPM) at various concentrations on HaCaT 
282 
xxiii 
 
cell viability. Results were expressed as mean ± SD of three 
independent tests. * indicates p < 0.05 compared to the 
untreated control 
 
Figure 6.3 Effect of native curcuminoids, native quercetin, 
curcuminoids microcapsule (CPM) and quercetin 
microcapsule (QPM) on HaCaT cell proliferation. Each 
point represents the mean of three independent tests 
 
283 
Figure 6.4 Effect of native curcuminoids, native quercetin, 
curcuminoids microcapsule (CPM) and quercetin 
microcapsule (QPM) on scratch wound repair of HaCaT 
cells. Results were expressed as mean ± SD of three 
independent tests 
 
285 
Figure 6.5 Effect of cream base, Silfazine cream (positive control), 
CPM cream and QPM cream on wound contraction 
compared to normal saline negative control group (n = 6). 
Results were expressed as mean ± S.E.M. * and ** indicate 
significant difference at p < 0.05 and p < 0.01, respectively 
compared to normal saline treated group 
 
286 
Figure 6.6 Effect of cream base, Silfazine cream (positive control), 
CPM cream and QPM cream on hydroxyproline content in 
wound tissue compared to normal saline negative control 
group (n = 6). Results were expressed as mean ± S.E.M. * 
and ** indicate significant level at p < 0.05 and p < 0.01, 
respectively compared to normal saline treated group 
292 
 
 
 
 
 
 
 
 
 
 
 
xxiv 
 
LIST OF PLATES 
  Page 
Plate 3.1 Micrographs show the coacervation of the gelatin-chitosan 
system at total polymer concentration of 2.55% w/w and 
mixing ratio of 30:1, with different pH values: (a) pH 4.75, 
(b) pH 5.00, (c) pH 5.25, (d) pH 5.50, (e) pH 5.75, and (f) 
pH 6.00. Bar represents 20 µm 
 
82 
Plate 3.2 Coacervation and precipitation systems obtained from 
gelatin-chitosan colloids at 2.55% w/w of different mixing 
ratios induced at pH 5.50 
 
83 
Plate 3.3 Micrographs show the gelatin-chitosan systems at total 
polymer concentration of 2.55% w/w with different ratios: 
(a) 10:1, (b) 15:1, (c) 20:1, (d) 25:1, (e) 30:1, (f) 35:1, (g) 
40:1, (h) 50:1, (i) 60:1, and (j) 80:1. Bar represents 20 µm 
 
86 
Plate 3.4 Micrographs show the gelatin-chitosan systems at ratio 30:1, 
with different total polymer concentrations: (a) 1.55, (b) 
2.05, (c) 2.55, (d) 3.05, and (e) 3.55% w/w. Bar represents 
20 µm 
 
87 
Plate 3.5 The physical appearance of the gelatinized gelatin-chitosan 
colloids at total polymer concentration of 2.55% w/w and 
mixing ratios from 10:1 to 80:1. 
 
88 
Plate 3.6 The physical appearance of the gelatin-chitosan systems at 
total polymer concentration of 2.55% w/w and mixing ratio 
of 30:1 equilibrated at different coacervation durations 
 
93 
Plate 4.1 Micrographs show the curcuminoids solid core 
microcapsules’ configuration by the effect of pH changing 
rate: (a) 25 µl/10 sec, (b) 50 µl/10 sec, (c) 100 µl/10 sec and 
(d) 200 µl/10 sec. Bars represent 10 µm 
 
126 
Plate 4.2 Micrographs show the effect of agitation rate during 
microencapsulation on configuration of curcuminoids solid 
core microcapsules: (a) 400 rpm, (b) 500 rpm, (c) 600 rpm 
and (d) 700 rpm. Bars represent 10 µm 
 
133 
Plate 4.3 Micrographs show the morphologies of (a) curcuminoids 
powder and (b) quercetin powder. Bar represents 20 µm  
 
137 
Plate 4.4 Micrographs show the configurations of microcapsules: (a) 
CLM, curcuminoids liquid core microcapsule; (b) QLM, 
quercetin liquid core microcapsule; (c) CPM, curcuminoids 
solid core microcapsule (d) QPM, quercetin solid core 
microcapsule (e) aggregate CPM, and (f) aggregate QPM. 
Bars represent 5 µm (a & b), 2 µm (c & d) and 1 µm (e & f), 
139 
xxv 
 
respectively 
 
Plate 4.5 Micrographs show the double layer of capsule wall in (a): 
CLM, curcuminoids liquid core microcapsule and (b): single 
layer of capsule wall in CPM, curcuminoids solid core 
microcapsule 
 
140 
Plate 4.6 SEMs for (a) crosslinked CPM and (b) uncrosslinked CPM 
 
142 
Plate 4.7 Pictures show the physical appearance and the staining effect 
of: (a) native curcuminoids powder, (b) curcuminoids solid 
core microcapsule powder, CPM and (c) curcuminoids liquid 
core microcapsule powder, CLM 
 
145 
Plate 4.8 Pictures show the physical appearance and the staining effect 
of: (a) native quercetin powder, (b) quercetin solid core 
microcapsule powder, QPM and (c) quercetin liquid core 
microcapsule powder, QLM 
 
146 
Plate 5.1 Micrographs show the emulsion droplet configurations 
produced by (a) mechanical mixing at 2000 rpm for 15 min, 
(b) mechanical mixing and homogenization at 18000 rpm for 
2 min, and (c) mechanical mixing and homogenization at 
18000 rpm for 2 min, 3 cycles. Bars represent 50 µm 
 
222 
Plate 5.2 Photos show the physical appearance of cream base, 
quercetin microcapsule (QPM) cream and curcuminoids 
microcapsule (CPM) cream  
 
223 
Plate 5.3 Methylene blue being dissolved and homogeneously diffused 
throughout the external phase of the O/W cream  
 
225 
Plate 5.4 Micrographs of (a) curcuminoids microcapsule (CPM) cream 
and (b) quercetin microcapsule (QPM) cream. Bars represent 
5 µm  
 
225 
Plate 5.5 Skin irritation test of curcuminoids microcapsule (CPM) 
cream – evidence and grading 
 
249 
Plate 5.6 Skin irritation test of quercetin microcapsule (QPM) cream – 
evidence and grading 
 
252 
Plate 6.1 Photographs of macroscopic appearance of wound 
contraction treated with normal saline at day 1 (a), day 3 (b), 
day 6 (c), day 9 (d), day 12 (e), day 15 (f), day 18 (g) and 
day 21 (h) 
 
287 
Plate 6.2 Photographs of macroscopic appearance of wound 
contraction treated with cream base 0.5 g/day at day 1 (a), 
day 3 (b), day 6 (c), day 9 (d), day 12 (e), day 15 (f), day 18 
288 
xxvi 
 
(g) and day 21 (h) 
 
Plate 6.3 Photographs of macroscopic appearance of wound 
contraction treated with Silfazine cream 0.5 g/day at day 1 
(a), day 3 (b), day 6 (c), day 9 (d), day 12 (e), day 15 (f), day 
18 (g) and day 21 (h) 
 
289 
Plate 6.4 Photographs of macroscopic appearance of wound 
contraction treated with CPM cream 0.5 g/day at day 1 (a), 
day 3 (b), day 6 (c), day 9 (d), day 12 (e), day 15 (f), day 18 
(g) and day 21 (h) 
 
290 
Plate 6.5 Photographs of macroscopic appearance of wound 
contraction treated with QPM cream 0.5 g/day at day 1 (a), 
day 3 (b), day 6 (c), day 9 (d), day 12 (e), day 15 (f), day 18 
(g) and day 21 (h) 
 
291 
Plate 6.6 Hematoxylin and Eosin stained section of skin burn wound 
from: (a) normal saline (negative control), (b) cream base-
treated, (c) Silfazine cream-treated, (d) CPM cream-treated 
and (e) QPM cream-treated groups; (E) Epidermis, (S) scab, 
(D) dermis, (EGT) early granulation tissue, (GT) granulation 
tissue, (star) aggregation of inflammatory cells, (R) rete 
ridges and (→) epithelialization 
294 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxvii 
 
LIST OF ABBREVIATIONS 
%T transmittance percent 
ߛሶ  Shear rate  
߬଴ Yield stress <  Less than 
> More than 
± Plus minus  
µg/ml Microgram per millimeter  
µl Microliter  
µm Micrometer 
ABTS 2,2’-azino-bis (3-ehylbenzothiazoline-6-sulfonate) 
BDMC Bisdemethoxycurcumin  
BHA Butylated hydroxyanisole 
BHT Butylated hydroxytoluene 
CLM Curcuminoid microcapsule (liquid core microencapsulation) 
cm Centimeter  
–COO-   Carboxylate  
-COOH Carboxyl group  
CPM Curcuminoid microcapsule (solid core microencapsulation) 
CUR Curcumin  
D[4,3] Volume mean diameter  
DMC Demethoxycurcumin  
DPPH 2,2-diphenyl-1-picrylhydrazyl 
DSC Differential scanning calorimetry 
FTIR Fourier transform infrared spectroscopy 
HCl Hydrochloric acid  
HLB Hydrophilic-lipophilic balance 
IP Intraperitoneal injection 
K Release rate constant or consistency coefficient 
k’ Capacity factor
LOD Limit of detection  
LOL Limit of linearity 
LOQ Limit of quantitation  
M Molar 
min Minute  
ml Milliliter  
ml/min Milliliter per minute 
mm Millimeter  
N Theoretical plate 
n Flow behavior index or release exponent 
Ƞ Apparent viscosity  
N2 Gas nitrogen 
NaCl Sodium chloride 
ng/ml Nanogram per millimeter  
-NH2 Amino group 
-NH3+  Ammonium  
nm Nanometer 
O/W Oil-in-water 
xxviii 
 
pHc Critical pH 
pHϕ pH of macroscopic/global phase separation,  
pI Isoelectric point  
QC Quality control  
QLM Quercetin microcapsule (liquid core microencapsulation) 
QPM Quercetin microcapsule (solid core microencapsulation) 
QUE Quercetin  
R Resolution  
R2 Coefficient of determination  
RH Relative humidity 
rHLB Hydrophilic-lipophilic balance requirement  
RP-HPLC Reversed phase high performance liquid chromatography 
rpm Rotation per minute 
RSD Relative standard deviation 
S.E.M Standard error of mean 
S/N Signal to noise 
SD Standard deviation 
SEM Scanning electron microscope 
Smix Emulsifiers blend 
t1/2 Half-life of degradation 
t50% Half-life of release 
t90 Shelf life or time of 10% decomposition 
Tf Tailing factor
tR Retention time 
UV Ultraviolet  
v/v Volume per volume 
W/O Water-in-oil 
w/w Weight per weight 
μM Micro molar  
τ Shear stress 
 
 
 
 
 
 
 
 
 
 
xxix 
 
LIST OF APPENDICES 
Appendix A1 Chromatograms of quercetin (10 µg/ml) and curcuminoids 
(100 µg/ml) 
 
Appendix B1 Formulation and method of preparation of type B gelatin-
chitosan mixture solution at different ratios and total polymer 
concentrations  
 
Appendix C1 Preparation of citrate-phosphate buffer 
 
Appendix C2 Preparation of citrate buffer 
 
Appendix D1 Calculation of required hydrophile-lipophile balance (rHLB) of 
oil phase ingredients 
 
Appendix D2 Calculation for relative quantities of emulsifying agents 
necessary to produce the physically stable emulsion  
 
Appendix E1 The drawing of straight lines from the middle of each apex to 
the opposite apex and the location of 27 screening points for 
fabrication of ternary phase diagram 
 
Appendix E2 Screening points and types of combination 
 
Appendix E3 Combination points constructed in the area of interest 
 
Appendix F1 Statistical analyses for apparent viscosity, firmness and work 
of shear 
 
Appendix G1 Approval letter for use of rabbits for primary skin irritation test 
 
Appendix G2 Approval letter for use of rats for wound healing study 
 
 
 
 
 
 
 
 
xxx 
 
MIKROKAPSUL KOASERVAT KOMPLEKS DALAM KRIM UNTUK 
PENGHANTARAN TOPIKAL KURKUMINOID DAN QUERCETIN  
 
ABSTRAK 
Kurkuminoid dan quercetin mempunyai aktiviti antioksidan, anti-radang dan 
anti-bakteria yang bermanfaat untuk penyembuhan luka. Walau bagaimanapun, sifat 
kedua-dua sebatian ini iaitu kelarutan dan bio-keperolehan yang rendah, 
fotosensitiviti dan pewarnaan menjadikan sebatian-sebation tersebut kurang sesuai 
untuk pemakaian topical. Oleh itu, objektif kajian ini adalah untuk membangunkan 
dan mencirikan mikrokapsul kurkuminoid dan quercetin, dan seterusnya 
menggabungkan sebatian-sebatian ini ke dalam krim. HPLC UV fasa terbalik 
isokratik dibangunkan dan disahkan untuk menyatakan kuantiti kurkuminoid 
(bisdemethoxycurcumin, demethoxycurcumin dan curcumin) dan quercetin secara 
serentak. Puncak quercetin, bisdemethoxycurcumin, demethoxycurcumin dan 
curcumin adalah terpisah dan simetri. Mikrokapsul telah disediakan dengan 
menggunakan kaedah koaservation kompleks menggunakan chitosan dan gelatin B. 
Mikrokapsul terbaik diperolehi dengan gelatin:chitosan pada nisbah 30:1 (2.55% 
w/w) dan pH 5.50. Kurkuminoid dikapsulkan sama ada dalam bentuk cecair (CLM) 
atau pepejal (CPM). Quercetin juga dikapsulkan sama ada dalam bentuk cecair 
(QLM) atau pepejal (QPM). Ciri-ciri fizikal bagi CPM dan QPM adalah lebih baik 
daripada CLM dan QLM. CPM dan QPM mempunyai saiz zarah dalam linkungan 
40-44 µm, kecekapan pemerangkapan sebanyak 82% dan memuatkan ubat 16%. 
Selain itu, mikrokapsul ini tidak melekit, kurang kesan pewarnaan dan stabil pada 
suhu bilik (28 °C) selama 12 bulan. Aktiviti antioksidan kurkuminoid dan quercetin 
adalah lebih tinggi daripada hidroksianisol dibutilkan (BHA) dan hidroksitoluena 
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dibutilkan (BHT). Tiada perubahan ketara dalam aktiviti antioksidan kurkuminoid 
dan quercetin selepas pengkapsulan dalam mikrokapsul. Kurkuminoid dan quercetin 
kemudiannya masing-masing digabungkan ke dalam asas krim O/W. Kedua-dua 
sediaan ini mempunyai ciri-ciri pseudoplastik dan tiksotropik. Kajian pelepasan in 
vitro menunjukkan bahawa kurkuminoid dan quercetin dilepaskan dari mikrokapsul 
yang digabungkan di dalam krim mengikuti kinetic tertib sifar. Krim-krim CPM dan 
QPM stabil pada suhu bilik (28 °C) selama 6 bulan. Ujian kerengsaan kulit pada 
arnab menunjukkan bahawa kedua-dua sediaan tidak merengsa. Tambahan pula, 
kajian in vivo penyembuhan luka pada tikus menunjukkan bahawa krim CPM dan 
krim QPM mempunyai sifat penyembuhan luka. Kesimpulannya, mikrokapsul 
kurkuminoid dan quercetin yang digabungkan dalam krim telah berjaya disediakan. 
CPM mempunyai ciri-ciri penyembuhan luka yang lebih baik daripada QPM.    
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COMPLEX COACERVATED MICROCAPSULES IN CREAM 
FOR TOPICAL DELIVERY OF THE CURCUMINOIDS AND QUERCETIN 
 
ABSTRACT 
The curcuminoids and quercetin possess antioxidant, anti-inflammatory and 
antibacterial activities which are beneficial for wound healing. However, poor 
solubility, poor bioavailability, photosensitivity and color staining properties of these 
two compounds make them not acceptable for topical administrations. Therefore, the 
objectives of the present study were to develop and characterize the 
curcuminoids/quercetin microcapsules and subsequently incorporate them in cream. 
Isocratic reversed phase UV HPLC was developed and validated to quantify the 
curcuminoids (bisdemethoxycurcumin, demethoxycurcumin and curcumin) and 
quercetin simultaneously. The peaks of quercetin, bisdemethoxycurcumin, 
demethoxycurcumin and curcumin were well separated and symmetrical. The 
microcapsules were prepared by complex coacervation method using chitosan and 
gelatin B. The best microcapsules were obtained at gelatin:chitosan ratio of 30:1 
(2.55% w/w) and pH 5.50. The curcuminoids was encapsulated either in liquid 
(CLM) or solid (CPM) form. The quercetin was also encapsulated either in liquid 
(QLM) or solid (QPM) form. The physical characteristics of CPM and QPM were 
better than CLM and QLM. The CPM and QPM had particle size in the range of 40 – 
44 µm, entrapment efficiency of 82% and drug loading of 16%. Moreover, the 
microcapsules had free flowing, reduce color staining effect and stable at room 
temperature (28 °C) for 12 months. The antioxidant activity of the curcuminoids and 
quercetin was higher than butylated hydroxyanisole (BHA) and butylated 
hydroxytoluene (BHT). There was no significant change in antioxidant activity of the 
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curcuminoids and quercetin after encapsulation in microcapsules. The curcuminoids 
and quercetin microcapsules were then incorporated in O/W cream base, 
respectively. The preparations had pseudoplastic and thixotropic properties. In vitro 
release study revealed that the curcuminoids and quercetin released from 
microcapsule incorporated in cream followed zero order kinetics. The CPM and 
QPM creams were stable at room temperature (28 °C) for 6 months. The skin 
irritation test in rabbit revealed that both preparations were nonirritant. Furthermore, 
the in vivo wound healing study in rats showed that CPM and QPM creams had 
wound healing properties. In conclusion, the curcuminoids and quercetin 
microcapsules incorporated in creams were successfully prepared. CPM had better 
wound healing property than QPM.  
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
CHAPTER 1 
INTRODUCTION 
 
1.1 Active ingredients 
1.1.1 Curcuminoids/curcumin 
The turmeric plant is a herb belonging to Curcuma longa L. (Zingiberaceae 
family) and has been widely used for centuries as a dietary spice and coloring agent 
in Indian and Chinese cuisines. The dried ground rhizome of the plant has been used 
in Asian medicine since the second millennium BC. Extracts of the rhizome 
including turmerin (a water-soluble peptide), essential oil (e.g., turmerones, 
atlantones and zingiberene) and curcuminoids [consists of curcumin (~77%), 
demethoxycurcumin (~17%), bisdemethoxycurcumin (~3%) and cyclocurcumin] 
(Akbik et al., 2014; Maheshwari et al., 2006; Naksuriya et al., 2014; Prasad et al., 
2014; Sharma et al., 2005).  
The three major analogues of the curcuminoids namely, curcumin, 
demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC) differ by a 
methoxy substitution on the aromatic ring (Figure 1.1). Curcumin has two symmetric 
o-methoxy phenols linked through the α,β-unsaturated β-diketone moiety, DMC has 
an asymmetric structure with one of the phenyl rings having o-methoxy substitution, 
and BDMC is similar to curcumin with its symmetric structure but is deficient in two 
o-methoxy substitutions. These analogues have different potential in terms of 
bioactivities (Anand et al., 2008). 
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Curcumin as the major component of curcuminoids is responsible for the 
yellow color that consists of 3-6% of turmeric preparations. Curcumin was 
discovered about two centuries ago by Vogel and Pelletier in the year 1815 (cited by 
Prasad et al., 2014). In year 1910, the chemical structure of curcumin [i.e., 
diferulyoylmethane or 1,7-bis (4-hydroxy-3-methoxy-phenyl) hepta-1,6-diene-3,5-
dione), C21H20O6] was reported by Milobedzka et al. (1910), as cited in Prasad et al. 
(2014). The first synthesis and chromatographic quantitation of curcumin were 
reported in years 1913 and 1953, respectively. Curcumin is practically insoluble in 
water at acidic and neutral pH but is soluble in methanol, ethanol, dimethylsulfoxide, 
and acetone. It has pKa value of 8.54 (Prasad et al., 2014). Curcumin exist in two 
molecular configurations that are, bis-keto and enolate. The keto form predominates 
in acidic and neutral conditions and in the solid phase, where curcumin acts as a 
potent donor of hydrogen atoms. The enol form consists of three ionizable protons 
corresponding to the enolic group and two phenolic groups, which predominate in 
alkaline conditions. However, curcumin is photosensitive and unstable in phosphate 
buffer systems of pH 7.2 (Goel et al., 2008; Strimpakos & Sharma, 2008; Wang et al., 
1997). 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Chemical structures of curcumin, demethoxycurcumin and 
bisdemethoxycurcumin. 
 
The biological characteristics of curcumin derivatives (demethoxycurcumin 
and bisdemethoxycurcumin) and curcumin were scientifically investigated in the 
mid-twentieth century (Prasad et al., 2014). Curcumin and derivatives of curcumin 
are typical flavonoid compounds, exhibit a wide range of pharmacological activities, 
such as anti-cancer (Anto et al., 1996; Ruby et al., 1995; Panahi et al., 2014), 
antioxidant (Jayaprakasha et al., 2006), anti-angiogenic (Gururaj et al, 2002; Kant et 
al., 2015), antibacterial (Sivasothy et al., 2013), anti-inflammatory (Kant et al., 2014), 
antiviral and antifungal (Anand et al., 2008). Curcumin is also a multidrug resistance 
modulator (Xue et al., 2013). Additionally, the curcuminoids have been shown to 
Curcumin (~77%)
Demethoxycurcumin (~17%)
Bisdemethoxycurcumin (~3%)
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have medicinal properties against several acute and chronic diseases including type II 
diabetes, rheumatoid arthritis, multiple sclerosis, Alzheimer’s disease, Parkinson’s 
disease, cardiovascular diseases, allergies, atherosclerosis and certain types of cancer 
(Li & Zhang, 2014; Maheshwari et al., 2006; Srivastava et al., 2011; Villaflores et al., 
2012). Curcuminoids have been explored in enhancement of wound healing, 
hepatoprotection, treatment of inflammatory disease, neoplastic disease, 
neurodegenerative disease, cystic fibrosis and cholesterol-lowering (Akbik et al., 
2014; Cao et al., 2015; Castangia et al., 2014; Kant et al., 2014).  
In vivo studies show the safety of curcumin following acute and subchronic 
administration to rats and mice.  High doses of dietary curcumin show no adverse 
effects in humans and animals (Sharma et al., 2005).  
1.1.2 Quercetin 
Quercetin is a flavonol compound belonging to a broad group of polyphenolic 
flavonoids. Quercetin is present in food as quercetin glycosides which represent 60-
75% of the total dietary flavonols plus flavones intake (Perez-Vizcaino et al., 2009). 
It is naturally-occurring in fruits and vegetables, such as apples, cranberries and 
onions. It is also found in black tea, red wine and various fruit juices. In the United 
States, the consumption of flavonol glycosides which are expressed as quercetin 
equivalents are at levels of up to ~100 mg/day, the total flavonoids (including 
flavanones, flavones, flavonols, anthocyanins, catechins and biflavans) intake from a 
normal mixed diet is estimated as ~1g/day flavonoids (expressed as quercitrin 
equivalents, where one biflavan molecule is equal to 2 molecules of quercitrin) 
(Harwood et al., 2007).  
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Quercetin has the chemical structure of two benzene rings linked by a 
heterocyclic pyran or pyrone ring, and its chemical formula is 3,3’,4’5,7-
pentahydroxyflavone (Figure 1.2) (Harwood et al., 2007). The free hydroxyl groups 
and their mutual location determine the antioxidant activity of quercetin (Materska, 
2008). The B-ring hydroxyl configuration shows highest scavenging capacity in 
scavenging of reactive oxygen species and reactive nitrogen species. A 3’4’-catechol 
structure in the B-ring is the most potent scavenger of lipid peroxidation (Heim et al., 
2002).  
 
 
 
 
 
 
 
 
Figure 1.2. Chemical structure of quercetin. 
 
Quercetin is among the most potent antioxidant of the polyphenols. It shows 
scancenging activity to hydrogen peroxide (H2O2), oxygen (O2), as well as reactive 
nitrogen species (RNS) such as nitric oxide (NO) and peroxynitrite (cited in 
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Zimmerman et al., 2014). Additionally, quercetin exhibits numerous biological and 
pharmacological activities, such as cardioprotective, anti-mutagenic, antioxidant, 
anti-inflammatory, chelation, antilipoperoxidative, antiproliferative, anti-
carcinogenic and anti-angiogenic (Harwood et al., 2007; Russo et al., 2012). 
Quercetin is therapeutically effective for hypertension (Perez-Vizcaino et al., 2009), 
skin oxidative stress (Inal & Kahraman, 2000; Joshan & Singh, 2013; Kimura et al., 
2009; Manca et al., 2014), rheumatoid arthritis (Natarajan et al., 2010) and wound 
healing (Gomathi et al., 2003). In cancer treatment, quercetin also reacts as a 
multidrug resistance modulator and thus a potential chemosensitizer (Chen et al., 
2010). In addition, quercetin has been shown to be chemopreventive and a possible 
solution for anthracycline-induced cardiotoxicity and multidrug resistance (Czepas & 
Gwoździński, 2014).  
Long-term oral animal toxicity studies demonstrated the safety of dietary 
quercetin (Harwood et al., 2007).   
 
1.2 Microencapsulation 
1.2.1 Introduction of microencapsulation 
Microencapsulation which has been developed since the 1950s is defined as a 
process of surrounding or enveloping the substance of either solids, liquids, or 
gaseous materials in a coating or capsule, yielding capsules ranging from sub-micron 
to several millimeters in size (Fang & Bhandari, 2010). The microencapsulation 
methods distinguishes the capsules in term of particle size ranges or denomination of 
either nanocapsules (size range smaller than 0.2 µm), microcapsules (size range 
between 0.2 and 5000 µm) or macrocapsules (size range larger than 5000 µm) 
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(Barbosa-Cánovas et al., 2005). The encapsulated substance is called core material, 
active ingredient or agent, fill, payload, internal phase or nucleus. On the other hand, 
the material encapsulating the core is called coating, membrane, shell, carrier or wall 
material. The coating materials can be sugars, gums, proteins, polysaccharides, lipids 
and synthetic polymers (Barbosa-Cánovas et al., 2005; Fang & Bhandari, 2010).  
Several conformations of microcapsules can be produced for encapsulation. 
The three main conformations are: single particle structure (regular or irregular), 
aggregate structure and multi-walled structure. Single structure microcapsule is a 
sphere of the active ingredient surrounded by a thick uniform wall. An aggregate 
structure is asymmetrically and variably shaped, with several distinct core particles 
embedded throughout the microcapsule. This type of microcapsules may have 
multiple core structure. The multi-walled microcapsules have different concentric 
layers which either have the same, or quite different compositions (Gibbs et al., 1999; 
Sachan et al., 2006). Microcapsules also present in multi-core structure and matrix. 
Multi-core microcapsules have a number of different sized chambers within the shell 
(Kumar et al., 2011). Figure 1.3 shows various morphologies of microcapsules. The 
morphology of the internal structure of microcapsules is influenced by the 
encapsulation techniques, the types of core materials and coating materials used. 
Liquid or dispersion of core material to be encapsulated will result in perfect 
microcapsules rather than solid core (Sachan et al., 2006). 
 
 
 
 
 
 
 
 
 
 
Figure 1.3
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1.2.2 Core material 
The core material which is the material to be coated to serve the specific 
purpose can be liquid or solid in nature. The composition of core material can be 
varied, such as liquids and dispersion forms for liquid core materials, while active 
constituents, stabilizers, diluents, excipients and release-rate retardants or 
accelerators are examples of solid core materials. The composition of core material is 
selected depending on the final microcapsules properties (Bansode et al., 2010; 
Sachan et al., 2006). 
1.2.3 Coating material  
A wide variety of coating materials are available for microencapsulation, 
depending on the material to be coated and the characteristics desired in the final 
microcapsules (Barbosa-Cánovas et al., 2005). Effective coating materials should 
meet the properties such as film forming, strength, pliable, tasteless, stable, non-
hygroscopic, soluble in aqueous media, good rheological at high concentration and 
ease of manipulation during the process of encapsulation and optical properties. 
Furthermore, the selected coating material should be chemically compatible and 
nonreactive with the core material during processing and storage. Additionally, it 
should meet the requirement of the system such as microcapsules solubility 
properties and core material release properties (Bansode et al., 2010; Barbosa-
Cánovas et al., 2005; Sachan et al., 2006). Examples of coating materials are as 
follows (Bansode et al., 2010):  
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(i) Water soluble resins: gelatin, gum arabic, starch, polyvinylpyrrolidone, 
carboxymethylenecellulose, hydroxyethylcellulose, methylcellulose, arabinogalactan, 
polyvinyl alcohol, polyacrylic acid; 
(ii) Water insoluble resins: ethylcellulose, polyethylene, polymethacrylate, 
polyamide (nylon), poly (ethylenevinyl acetate), cellulose nitrate, silicones, 
poly(lactide-co-glycolide); 
(iii) Waxes and lipids: paraffin, carnauba, spermaceti, beeswax, stearic acid, stearyl 
alcohol. Glyceryl stearates; and 
(iv) Enteric resins: shellac, cellulose, acetate phthalate, zein. 
1.2.3 (a) Gelatin 
Gelatin is derived from the fibrous protein collagen by the process of partial 
hydrolysis; collagen which is broadly found as the major component of animal skin, 
bones and connective tissue (Karim & Bhat, 2009; Mukherjee & Rosolen, 2013). 
Depending on the hydrolysis process which is the method by which collagen is 
pretreated, two types of gelatin are available, namely, type A and type B gelatins 
(Karim & Bhat, 2009; Singh et al., 2002). Type A gelatin is derived from acid 
processed collagen (isoelectric point at pH 6-9), while type B gelatin is derived from 
alkaline processed collagen (isoelectric point at approximately pH 5) (Karim & Bhat, 
2009). The acid or base precursor results in different characteristic features of gelatin 
due to different number of NH2 and COOH groups on the gelatin molecules (Siow & 
Ong, 2013). 
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Collagen molecules are composed of three α-chains which consist of 
continuous repetitions of Gly-X-Y amino acid sequences where X is mostly proline 
and Y is mostly hydroxyproline (Eastoe & Leach, 1977), forming a triple-helix 
structure. The intertwined triple-helix adopts a 3D structure that provides an ideal 
geometry for inter-chain hydrogen bonds. The triple-helices are stabilized by the 
inter-chain hydrogen bonds (Duconseille et al., 2015; Karim & Bhat, 2009). 
Denaturation of collagen by thermal or physical and chemical means causes the 
destruction of hydrogen bonds, which results in breaking of the triple-helix structure 
into random coils to produce gelatin (Bigi et al., 2004; Karim & Bhat, 2009). Gelatin 
contains amino acids in varying composition as reported by Eastoe (1955). The 
amino acid composition of gelatin is very close to that of its parent collagen (Karim 
& Bhat, 2009). 
Gelatin is biodegradable, non-toxic, and easy to crosslink and to modify 
chemically. It is frequently used in food, pharmaceutical, biomedical and 
photographic industries. It is commonly used as the main ingredient of hard and soft 
capsules, microspheres, sealants for vascular prostheses, wound dressing and 
adsorbent pad for surgical use and tissue regeneration. Gelatin is soluble in aqueous 
solution at temperature of about 40 °C and present in the sol state (Bigi et al., 2004). 
When gelatin is cooled below 30-35 °C the random coil polypeptide chains will 
undergo a conformational disorder-order transition and partly regenerate the collagen 
triple-helix structure and form thermoreversible gels by associating helices in 
junction zones stabilized by hydrogen bonds (Bigi et al., 2004; Strauss & Gibson, 
2004). Because gelatin is soluble in aqueous solution, gelatin used as coating 
material or matrix of microcapsule products must be submitted to crosslinking, 
which improves both thermal and mechanical stability of the biopolymer (Bigi et al., 
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2004). Crosslinking is important for the gelatin capsules to be insoluble at high 
temperatures, to reduce swelling in water and decrease permeability across cell 
membranes. Formaldehyde and glutaraldehyde are the most common agents used in 
gelatin crosslinking.  
Gelatin is widely used as the main ingredient of the complex coacervation in 
the food and pharmaceutical industries (Comunian et al., 2013; Dong et al., 2011; 
Hanes et al., 2001; Jizomoto et al, 1993; Saravanan & Rao, 2010; Shinde Y 
Nagarsenker, 2011). The most important property of this protein is that gelatin is a 
polyampholyte with amine (-NH2) and carboxyl (-COOH) functional groups along 
with hydrophobic groups (lurea Raţă et al., 2013). Gelatin is a random coil polymer 
carrying positively and negatively charged-sites in almost 1:1 ratio. Additionally, it is 
associated with a small persistence length of about 2 nm (Bohidar, 2008).  In solution, 
gelatin can be ionized to either –COO- or - NH3+ depending on the pH of the solution. 
At pH above the isoelectric point, gelatin charged negatively; whereas at pH below 
the isoelectric point, gelatin charged positively. Hence, gelatin will react with 
oppositely charged biomolecules in the same medium via electrostatic interaction to 
form polyionic complexes (Young et al., 2005). For example, in a mixture containing 
gelatin (a protein) and an anionic polysaccharide, adjustment of the pH to below the 
isoelectric point (pI) or the electrical equivalence pH (IEP) of gelatin would result in 
maximum electrostatic attraction where the two biopolymers are carrying oppositely 
charge (Siow & Ong, 2013). For instance, complex coacervation occurred in a 
mixture of gum arabic (acacia) and type A gelatin at pH 4.5 (Bhattacharyya & 
Argillier, 2005; Siow & Ong, 2013), or occurred in a mixture of gum arabic (acacia) 
and type B gelatin at pH 3.5 (Siow & Ong, 2013). On the other hand, a gelatin-
cationic polysaccharide system requires the adjustment of the mixture pH to above 
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the isoelectric point of gelatin for electrostatic attraction. For instance, complex 
coacervation occurred in a type B gelatin-chitosan system at pH 5.25-5.5 (Remuñán-
López & Bodmeier, 1996). At pH 5.25-5.5, gelatin will be negatively charged (since 
the isoelectric point of gelatin B is 4.7-5.2) and it will electrostatically interact with 
positively charged chitosan to form an insoluble complex (complex coacervate). At 
such pH, gelatin-chitosan complex coacervation should be limited to type B gelatin. 
The isoelectric point of type A gelatin is typically 8-9, so its complex coacervation 
with chitosan should be limited to pH values above this (Thies, 2007). However, 
chitosan is precipitated at solution of pH higher than 6 since the pKa of chitosan is 
about pH 6.3 (Paños et al., 2008). Figure 1.4 shows the chemical structure of gelatin. 
 
 
Figure 1.4. Chemical structure of gelatin. 
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1.2.3 (b) Chitosan 
Chitosan is an amino-polysaccharide derived by alkaline deacetylation of chitin 
(an N-acetyl-glucosamine polymer). Chitin is the second most abundant polymer in 
nature after cellulose and is from crustaceans, exoskeleton of insects and fungi. 
Chitosan is a cationic polysaccharide, a copolymer of 2-acetamido-2-deoxy-β-D-
glucose and 2-amino-2-deoxy-β-D-glucose units, and it differs in the degree of N-
acetylation (40-98%) and molecular weight (50-2000 kDa) (Basu et al., 2010; 
Estevinho et al., 2013; Paños et al., 2008). The solubility of chitosan, which has a 
pKa value of 6.3 (Paños et al., 2008), depends closely on the degree of acetylation 
(Kumirska et al., 2011) where it is normally insoluble in aqueous solutions of pH 
value higher than pKa, however it is soluble in dilute acid solutions below pH 6.5 
(Riva et al., 2011). The protonated free amino groups facilitate the solubility of the 
molecule and characterize chitosan as a cationic polyelectrolyte (Kumirska et al., 
2011). The chemical structure of chitosan is shown in Figure 1.5. 
 
 
Figure 1.5. Chemical structure of chitosan. 
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Chitosan has been widely used in food, cosmetic and pharmaceutical industries 
as a carrier for drug delivery because it possesses excellent properties, such as non-
toxicity, biodegradability, biocompatibility and absorption properties (Paños et al., 
2008). Additionally, a large number of amine groups provide availability of chitosan 
interacting with other substances (Jaya et al., 2010). Since the 90’s, chitosan 
microspheres have been used as controlled drug delivery systems for conventional 
drugs, protein drugs and bioactive compounds. Chitosan is particularly useful as 
coating material in microencapsulation for controlled release of bioactive compounds. 
Chitosan can establish covalent or ionic bonds with the crosslinking agents, for 
example, glutaraldehyde which form Schiff bases with amino groups building three 
dimensional network, thus increases the internal surface area for absorption and the 
encapsulated active substance stays retained, and consequently as controlled release 
carrier (Estevinho et al., 2013; Jaya et al., 2010). On the other hand, chitosan and its 
derivatives in microencapsulation of peptides and proteins have proven to enhance 
their permeation, since they have affinity for enzymes that usually degrade the 
peptide (e.g., insulin). Hence, the bioavailability of peptide drugs is increased due to 
permeation enhancement by chitosan, its enzyme inhibition and mucoadhesive 
properties (Paños et al., 2008). 
Chitosan is a good coating material candidate for different microencapsulation 
techniques because its cationic properties in acidic conditions make it able to 
electrostatically interact with negatively charged molecules or polymers (Riva et al., 
2011). Chitosan can form nanoparticles by ionic gelation with polyphosphates and 
with nucleic (Riva et al., 2011). In addition, chitosan is used for simple coacervation 
together with incompatible material, such as sodium sulphate. Simple coacervation is 
a simple and mild method, however, results in low encapsulation efficiency (Paños et 
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al., 2008). Chitosan is also used for complex coacervation with type B gelatin since 
one behaves cationic and the other behaves anionic in solutions at pH value above 
the isoelectric point of gelatin. Besides, complex coacervation between chitosan and 
the negatively charged lipid, lecithin has produced nanoparticles. Sodium alginate-
chitosan systems have been widely studied. The release of albumin 
microencapsulated in this system is influenced by the molecular weight of chitosan 
used (Paños et al., 2008).   
1.2.4 Crosslinking agent  
Crosslinking is a process of hardening of microcapsules which can improve 
microcapsule stability via formation of covalent bonds between molecule chains to 
form a three-dimensional network of connected molecules. The crosslinking agents 
can be chemical or enzymatic, and usually are molecules with at least two reactive 
functional groups that allow the formation of bridges between polymeric chains by 
covalent bonds (Estevinho et al., 2013). Covalent crosslinking of microcapsules 
allows drug release by diffusion due to absorption of water and/or bioactive 
compounds instead of dissolution (Estevinho et al., 2013). Aldehydes such as 
glutaraldehyde, formaldehyde and glyceraldehye are the most commonly used 
chemical crosslinkers in microencapsulation of polymers which contain amino 
groups (Hernández-Muñoz et al., 2004b). However, due to the possible toxicity of 
chemical crosslinkers, enzymatic crosslinkers such as transgutaminase is usually 
applied in microencapsulation of food ingredients (De Jong & Koppelman, 2002; 
Dong et al., 2008). 
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Aldehyde group of formaldehyde reacts with amine group of matrix leading to 
dehydration of the methylol intermediate to yield an active Schiff base. This is a fast 
process. (2) Following the polymerization of formaldehyde, the Schiff base reacts 
with another amine group to form cross-link –CH2- (methylene bridge) (Wu et al., 
2011). The formation of methylene bridges proceeds much more slowly compared to 
the first step. In collagen crosslinking with formaldehyde, the crosslink most often 
occurs between the nitrogen atom at the end of the side-chain of lysine and the 
nitrogen atom of a peptide linkage (Figure 1.7) (Kiernan, 2000). Such number of 
crosslinks increases with time and can lead to an intermolecular and intramolecular 
crosslinking network (Kiernan, 2000). In addition, collagenous samples such as 
gelatin may form inter- and intramolecular crosslinks with cyclic structure within 
collagen fibers (Bigi et al., 2004).   
 
 
 
 
 
 
 
 
Figure 1.7. Formaldehyde crosslinking: formation of methylene glycol and 
methylene bridge. Adapted from Kiernan (2000).  
19 
 
 
Inner cavity 
Core
Drug Drug 
Matrix
(a) (b) 
Capsule shell 
 1.2.5 Classification of microcapsules and microspheres 
Microparticles can be classified according to their structure, namely, 
microcapsules and microspheres. Microcapsules consist of a polymeric shell 
(envelope or wall) and an encapsulated active product (core material) located within 
the shell. Thus, the core and the wall are well-defined in microcapsule systems. 
Microspheres are in strict sense, spherical empty particles because the drug substance 
is either homogeneously dissolved or dispersed in a polymeric matrix, thus no well-
defined wall exists (Kumar et al., 2011; Kvitnitsky et al., 2005). In addition, for large 
size particles, microbeads, beads, spheres and spherical particles are also terms used 
alternatively for microcapsules and microspheres (Kvitnitsky et al., 2005). Figure 1.8 
shows the morphologies of microcapsule and microspheres. Microspheres are 
essentially spherical in shape, whereas microcapsules may be spherical or irregular in 
shape. 
 
 
 
 
 
Figure 1.8. Schematic morphologies of (a) microcapsule and (b) microsphere. 
Adapted from Lembo and Cavalli (2010). 
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1.2.6 Coacervation microencapsulation 
Coacervation encapsulation is a physiochemical process, and is classified as 
simple or complex. Simple coacervation systems only contain one colloidal solute 
(e.g., only gelatin), while in complex coacervation systems contain more than one 
solute (e.g., gelatin and gum acacia) (Barbosa-Cánovas et al., 2005). In general, this 
technology consists of three steps which are carried out under continuous agitation, 
that include: (1) formation of three immiscible chemical phases, (2) deposition of 
coating, and (3) rigidization of the coating. Briefly, the coacervation 
microencapsulation process is initiated by either changing the pH or temperature of 
the colloidal system, or adding a non-solvent or another complete chemical (e.g., 
sodium sulfate) to the colloidal system which contains the active ingredient (core 
material). Consequently, a two-phase system is created that consist of the colloid-rich 
phase (appearing as an amorphous cloud) and the colloid-poor phase/aqueous phase. 
Deposition of the newly formed coacervate phase around the active ingredient (core 
material) suspended or emulsified in the same reaction media forms small and still 
unstable microcapsules. Rigidization of the capsule wall can be done by crosslinking 
with chemical crosslinker (e.g., glutaraldehdye) or enzymatic crosslinker (e.g., 
transglutaminase), or by adjusting temperature or pH of the colloid system. The final 
steps of the process include collecting, washing and drying (Barbosa-Cánovas et al., 
2005; Gouin, 2004; Sachan et al., 2006). This is a high payload microencapsulation 
technique, up to 99% with achievable yield (Gouin, 2004).   
1.2.6 (a) Complex coacervation systems 
Complex coacervation was first introduced by Bungenberg de Jong (1929) in 
their investigation for the system of gelatin-gum arabic. The name complex 
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coacervation is to distinguish from simple coacervation where the complex 
coacervation process involves the interaction of two oppositely charged 
polyelectrolytes as opposed to the simple coacervation that is based on single 
biopolymer. Complex coacervation is a liquid-liquid phase separation phenomenon 
that occurs as a consequence of electrostatic interaction between the two oppositely 
charged polyelectrolytes in a solution (Milanović et al., 2014). The neutralization of 
the opposite net charges of polyelectrolytes in the mixed solution separates the 
solution into a highly concentrated coacervate phase in the form of microdroplets and 
a dilute bulk phase (Bungenberg de Jong, 1949; Strauss & Gibson, 2004).  
Complex coacervation may result in a mixture of oppositely charged 
polyelectrolytes (PE-PE) and polyelectrolytes with oppositely charged colloids 
(colloid-PE), such as micelles, proteins or dendrimers in aqueous media (Kizilay et 
al., 2011). Gelatin A-gelatin B and gelatin B-chitosan systems are examples of PE-
PE and colloid-PE coacervations, respectively. Figure 1.9 illustrates the process of 
microencapsulation by complex coacervation. 
1.2.6 (b) Complex coacervation microencapsulation process 
The deposition of the coacervate onto the core droplets to form the 
microcapsule shell and maintain the integrity of shell and size depend on several 
processing parameters. These parameters include polymer type, molecular weight, 
charge density, concentration of polymers and their ratio, pH and temperature of the 
system, and cooling rate. Among these factors, pH of the coacervation system and 
polymers mixing ratio are the most studied factors in complex coacervation 
microencapsulation (Koh & Tucker, 2011; Liu et al., 2009; Shinde & Nagarsenker, 
2009; Wang et al., 2014; Xiao et al., 2011). This is because improper mixing ratio of 
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oppositely charged polyelectrolyte can cause precipitation due to imbalance of 
charge density.  
During the coacervation process, the temperature is above the melting point of 
colloid polymer (i.e., gelatin) under constant stirring, thus coacervate formed is 
initially a liquid. This allows the coacervate to engulf the dispersed core material 
droplets or particles, thereby coating them with a thin film of liquid coacervate. 
Thereafter, cooling of the coacervates below its gel temperature will settle the gel 
structure of the coacervate (Thies, 2007). For example, when gelatin gel is cooled 
below melt temperature results the random coil polypeptide chains link up to form 
collagen-like triple helices for part of their length (Strauss & Gibson, 2004). This 
transforms the thin liquid film that surrounds the small droplets of core material into 
a thin gel coating. The changes of temperature not only change the coacervate from 
liquid form to gel form, but also change the viscosity and rheology of the coacervate, 
thereby producing a major impact on the success of a complex coacervation 
encapsulation process (Thies, 2007). Crosslinking of microcapsules has improved its 
stability against mechanical force and modified drug release (Alvim & Grosso, 2010). 
Figure 1.10 illustrates the formation of microcapsules by coacervation. 
 
 
 
 
 
23 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Process of microencapsulation by complex coacervation: (a) 
emulsification or suspension of core ingredients in the vehicle phase (typically 
aqueous solution); (b) induce complex coacervation by addition of a second 
complexing hydrocolloid; (c) solidification of wall materials and crosslink to 
stabilize the microcapsules; and (d) washing and drying. 
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